- Home
- RYN vs VKTX Comparison
RYN vs VKTX Comparison
Compare RYN & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYN
- VKTX
- Stock Information
- Founded
- RYN 1926
- VKTX 2012
- Country
- RYN United States
- VKTX United States
- Employees
- RYN N/A
- VKTX N/A
- Industry
- RYN Real Estate Investment Trusts
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- RYN Real Estate
- VKTX Health Care
- Exchange
- RYN Nasdaq
- VKTX Nasdaq
- Market Cap
- RYN 3.7B
- VKTX 3.8B
- IPO Year
- RYN N/A
- VKTX 2015
- Fundamental
- Price
- RYN $24.72
- VKTX $32.97
- Analyst Decision
- RYN Hold
- VKTX Strong Buy
- Analyst Count
- RYN 4
- VKTX 12
- Target Price
- RYN $28.00
- VKTX $86.42
- AVG Volume (30 Days)
- RYN 1.1M
- VKTX 4.7M
- Earning Date
- RYN 11-05-2025
- VKTX 10-22-2025
- Dividend Yield
- RYN 11.70%
- VKTX N/A
- EPS Growth
- RYN 389.17
- VKTX N/A
- EPS
- RYN 4.92
- VKTX N/A
- Revenue
- RYN $1,239,943,000.00
- VKTX N/A
- Revenue This Year
- RYN N/A
- VKTX N/A
- Revenue Next Year
- RYN $2.18
- VKTX N/A
- P/E Ratio
- RYN $5.02
- VKTX N/A
- Revenue Growth
- RYN 40.53
- VKTX N/A
- 52 Week Low
- RYN $21.84
- VKTX $18.92
- 52 Week High
- RYN $32.88
- VKTX $81.73
- Technical
- Relative Strength Index (RSI)
- RYN 40.34
- VKTX 56.75
- Support Level
- RYN $24.09
- VKTX $32.76
- Resistance Level
- RYN $25.29
- VKTX $34.92
- Average True Range (ATR)
- RYN 0.66
- VKTX 1.90
- MACD
- RYN -0.19
- VKTX 0.27
- Stochastic Oscillator
- RYN 21.04
- VKTX 60.50
About RYN Rayonier Inc. REIT
Rayonier owns and manages over 2 million acres of timberland in the United States. It is one the largest private landowners in North America. Rayonier is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.